{
  "id": 10630655,
  "title": "Stifel upgrades STAAR Surgical stock rating on China growth outlook",
  "url": "https://urgent.news/2026/09/29/stifel-upgrades-staar-surgical-stock-rating-on-china-growth-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T06:54:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/stifel-upgrades-staar-surgical-stock-rating-on-china-growth-outlook-93CH-4921652"
  },
  "original_language": "en",
  "account": "Investing.com reports that Stifel upgraded STAAR Surgical's stock rating from Hold to Buy, and raised its price target from $28 to $31 on Monday. The current stock price of $20.87 is below the analyst's Fair Value estimate of $26.45, suggesting potential undervaluation. Analyst Thomas M. Stephan anticipates a sales growth trajectory in the second half of 2026, fueled by China's shift towards the higher-priced EVO+ product mix and more favorable market comparisons in other regions. Stifel expects China revenue growth to materialize in 2027, coinciding with the end of Middle East headwinds. Demonstrating solid momentum, STAAR Surgical has achieved 51% revenue growth over the past year, with an impressive gross profit margin of 77%. The company holds more cash than debt, providing financial flexibility for growth initiatives. In the 2028 scenario analysis, Stifel predicts an 11% compound annual growth rate in sales from 2026 to 2028, compared to the current consensus estimate of 8%. The $31 price target is based on a 3.5 times enterprise value-to-sales multiple, contrasted with the current range of 2.0 to 2.5 times. While the company's pipeline and research and development efforts are early and uncertain, the long-term potential of addressing presbyopia through its ICL product is compelling, given the vast addressable market. Despite second-quarter 2026 revenue of $93.5 million, exceeding expectations of $90.17 million, adjusted earnings per share fell short of forecasts at $0.16 compared to the expected $0.22. China's contributions to performance were substantial, with sales rising 10% sequentially to $52.3 million, driven by market share gains and the adoption of the EVO+ product. Analyst reactions have been mixed; Stifel lowered its price target to $28 from $31, but Jefferies and Piper Sandler maintained a Hold rating and Neutral rating, respectively, with adjusted price targets of $28 and $33.",
  "summary": null,
  "key_points": [
    "Stifel upgrades STAAR Surgical stock rating to Buy from Hold.",
    "Analyst expects China revenue growth to start in 2027.",
    "STAAR Surgical shows 51% revenue growth over the past year."
  ],
  "editors_take": "Stifel's upgrade signals increased confidence in STAAR Surgical's growth prospects, driven by China's adoption of higher-priced products and favourable market comparisons, potentially unlocking undervaluation and fuelling sales growth.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}